Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 6/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20883687 | 0.84 | TLR9 (0.42) | HTR6HTR2CCHRNB2CHRNA4SLC6A2 | |
| SCHEMBL20883807 | 0.83 | HTR2C (0.39) | HTR6HTR2CCHRNB2CHRNA4SLC6A2 | |
| SCHEMBL20883993 | 0.83 | SLC6A2 (0.41) | CYP2D6HTR6HTR2CCHRNB2CHRNA4 | |
| SCHEMBL20883575 | 0.81 | HTR2C (0.37) | HTR6HTR2CCHRNB2CHRNA4SLC6A2 | |
| SCHEMBL20883992 | 0.78 | SLC6A2 (0.37) | HTR6HTR2CCHRNB2CHRNA4SLC6A2 | |
| SCHEMBL20458024 | 0.77 | HTR2C (0.54) | HTR6HTR2CCHRNB2CHRNA4SLC6A2 | |
| SCHEMBL20883989 | 0.77 | MMP9 (0.37) | HTR6HTR2CCHRNB2CHRNA4SLC6A2 | |
| SCHEMBL20883806 | 0.77 | SLC6A2 (0.36) | HTR6HTR2CCHRNB2CHRNA4SLC6A2 | |
| SCHEMBL15785387 | 0.76 | HTR6 (0.45) | HTR6HTR2CCHRNB2CHRNA4SLC6A2 | |
| SCHEMBL20883813 | 0.76 | HTR1D (0.38) | PLATHTR6HTR2CCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CYP1A2 3068/4885CYP2D6 829/4885PLAT 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.